z-logo
open-access-imgOpen Access
Immunohistochemical expression of interleukin 1 beta in papule biopsies from patients with acne vulgaris
Author(s) -
Le Thai Van Thanh,
Le Vi Anh,
Tran Huong Giang,
Ta Quoc Hung,
Van The Trung,
Nguyen Lam Vuong
Publication year - 2022
Publication title -
dermatology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.183
H-Index - 10
eISSN - 2036-7406
pISSN - 2036-7392
DOI - 10.4081/dr.2022.9444
Subject(s) - acne , papule , medicine , immunohistochemistry , biopsy , skin biopsy , pathology , disease , dermatology , gastroenterology , lesion
Background: Acne vulgaris is the most common inflammatory disease of the skin. IL-1b has been found in acne lesions and is a promising target for therapy, but the evidence is limited. Therefore, this study was conducted to investigate the immunohistochemical expression of IL-1b in papule biopsies of inflammatory acne and its association with disease severity. Methods: This study involved 20 patients with acne vulgaris (13 females, median age: 22 years). Samples were taken using punch biopsy. Immunohistochemical IL-1b expression was semiquantitatively assessed as absent, mild, moderate or strong. Disease severity was evaluated according to the Global Acne Grading System (GAGS). Results: There were 7 patients with mild disease and 11 patients with moderate disease. Median GAGS score was 20. Mild and moderate accounted for 65% and 30% for dermal IL-1b expression, 60% and 40% for epidermal expression, and 70% and 15% for perifollicular expression. Moderatestrong perifollicular expression had significant higher GAGS score than absent-mild expression (median: 22 versus 16). Conclusions: This study shows the elevated immunoreactivity of IL-1b in papule biopsies of inflammatory acne vulgaris. The levels of IL-1b expression also correlates with disease severity. IL- 1b could be a good candidate for targeting treatment of acne vulgaris.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here